Dear Sir,

The current seasonal trivalent influenza vaccine is not effective against the influenza A(H1N1)v virus, and a new monovalent vaccine against A(H1N1)v was developed and fast-track licenced \[[@ref1]\]. We report three renal transplant patients recently admitted with a serious bacterial infectious disease following adjuvanted A(H1N1)v vaccination.

Case 1: A 63-year-old male renal transplant (March 2003) recipient presented with subfebrile temperature of 37.9°C, cough and chest pain. Seven days before, he had been vaccinated against H1N1 by his general practitioner. For immunosuppression, cyclosporine A and prednisolone were taken. Chest X-ray showed a pneumonic infiltration in the right lower lung. Bronchoscopy was performed, and *Chlamydia pneumoniae* was cultured.

Case 2: A 46-year-old truck driver with a well-functioning renal transplant for 14 years experienced fever and malaise following H1N1 vaccination. He was commenced on sultamicillin for cystitis with a positive urine culture of enterococci. His immunosuppression was methylprednisolone and cyclosporin A. Since urine output declined, the patient presented to the emergency department, and intravenous ceftriaxone was begun.

Case 3: A 66-year-old renal transplant (March 2007) patient had received a H1N1 vaccination 1 week before developing cough, malaise and running nose. He presented to the transplant clinic 2 weeks later. Chest X-ray showed a pneumonic infiltrate in the lower lobe. For immunosuppression, he took prednisolone, cyclosporine A and mycophenolate mofetil. The patient was admitted for intravenous antibiotic therapy with ceftriaxone.

Prevention of influenza in organ transplant recipients is a crucial issue since evidence of the clinical effectiveness of immunization is lacking \[[@ref2]\], and some reports on vaccination in kidney transplant patients suggest a diminished antibody response dependent on the type of immunosuppression \[[@ref3]\].

Stimulation of a drug-modified immune system may result in unexpected reactions. The cell-mediated immune response peaks at 1 week after booster with inactivated influenza virus, but leukocyte migration is impaired \[[@ref4]\]. Induction of inflammatory cytokines by Toll-like receptor agonists at or after the time of dendritic cell immunization prevented the early acquisition of memory characteristics of corresponding CD8 T cells and did not promote further expansion of responding CD8 T cells. Thus, the host default pathway of memory CD8 T-cell differentiation was deflected by encounter with cytokines \[[@ref5]\].

All patients admitted in November 2009 suffered from bacterial infections after H1N1 vaccination ([Table 1](#tab1){ref-type="table"}). No admissions in association with vaccination in renal transplant patients have been seen so far ([Figure 1](#fig1){ref-type="fig"}). It can be speculated that an adequate immune response to bacterial infection 1 week after H1N1 vaccination was prevented by a non-specific immune modulation due to the application of an adjuvant. Furthermore, close surveillance of the adjuvanted H1N1 vaccine is mandatory. Non-adjuvanted vaccines may be preferred in transplant patients until the safety of adjuvanted vaccines is proven in this group of patients.

###### 

Laboratory values of three renal transplant patients suffering from infection following H1N1 vaccination

  Laboratory test (normal value)       Case 1                          Case 2                 Case 3
  ------------------------------------ ------------------------------- ---------------------- --------------------------------------------------
  Haemoglobin (8.6--12.0 mmol/l)       8.4                             7.2                    9.4
  White blood cells (3.8--9.8 Gpt/l)   7.0                             6.6                    6.9
  Platelets (150--430 Gpt/l)           130                             183                    297
  Differential blood count             Lymphopaenia 7.7%               Lymphopaenia 17.6%     Lymphopaenia 13.0%
  CD4 cells (420--2210 Mpt/l)          128                             N/A                    379
  CD8 cells (200--1190 Mpt/l)          37                              N/A                    170
  CD4/CD8 ratio (0.6--2.8)             3.5                             N/A                    2.2
  IgA (0.7--4.0 g/l)                   2.34                            N/A                    0.47
  IgG (7.0--16.0 g/l)                  6.08                            N/A                    11.58
  IgM (0.4--2.3 g/l)                   0.68                            N/A                    0.21
  INR                                  3.8                             0.98                   N/A
  Creatinine (35--106 µmol/l)          106                             310                    132
  Previous creatinine                  168                             177                    156
  C-reactive protein (\<5.0 mg/l)      187.7                           10.0                   16.9
  Cyclosporin A (80--120 µg/l)         137                             N/A                    98
  Urinary sediment                     Microhaematuria                 Leucocyturia           Proteinuria 113 g/mol creatinine,microhaematuria
  Microbiology                         Chlamydia in bronchial lavage   Enterococci in urine   N/A
  A(H1N1)v HA gene RNA PCR             Negative                        N/A                    Negative
  Anti-IgG A(H1N1)v                    1:2480                          N/A                    1:40
  Influenza antibody ELISA (IgA/IgG)   Positive/positive               N/A                    Positive/positive

All values are in SI units. N/A, not available; INR international normalized ratio.
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